Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects.

Journal Article

The biodistribution of radioactivity after the administration of a new tracer for alpha4beta2 nicotinic acetylcholine receptors (nAChRs), [123I]5-iodo-3-[2(S)-2-azetidinylmethoxy]pyridine (5-I-A-85380), was studied in ten healthy human subjects. Following administration of 98+/-6 MBq [123I]5-I-A-85380, serial whole-body images were acquired over 24 h and corrected for attenuation. One to four brain single-photon emission tomography (SPET) images were also acquired between 2.5 and 24 h. Estimates of radiation absorbed dose were calculated using MIRDOSE 3.1 with a dynamic bladder model and a dynamic gastrointestinal tract model. The estimates of the highest absorbed dose (microGy/MBq) were for the urinary bladder wall (71 and 140), lower large intestine wall (70 and 72), and upper large intestine wall (63 and 64), with 2.4-h and 4.8-h urine voiding intervals, respectively. The whole brain activity at the time of the initial whole-body imaging at 14 min was 5.0% of the injected dose. Consistent with the known distribution of alpha4beta2 nAChRs, SPET images showed the highest activity in the thalamus. These results suggest that [123I]5-I-A-85380 is a promising SPET agent to image alpha4beta2 nAChRs in humans, with acceptable dosimetry and high brain uptake.

Full Text

Duke Authors

Cited Authors

  • Fujita, M; Seibyl, JP; Vaupel, DB; Tamagnan, G; Early, M; Zoghbi, SS; Baldwin, RM; Horti, AG; KoreN, AO; Mukhin, AG; Khan, S; Bozkurt, A; Kimes, AS; London, ED; Innis, RB

Published Date

  • February 2002

Published In

Volume / Issue

  • 29 / 2

Start / End Page

  • 183 - 190

PubMed ID

  • 11926380

International Standard Serial Number (ISSN)

  • 1619-7070

Language

  • eng

Conference Location

  • Germany